CORRECTING and REPLACING - Inotiv Reports Third Quarter Financial Results for Fiscal 2025 and Provides Business Update

Written by Emily J. Thompson, Senior Investment Analyst

NOTV+2.19%

Updated: 08-07

3mins

NOTV.O

$1.400-49.091%Past 6 months

Line

Candle

YTD

Intellectia

Analyst Views on NOTV

Wall Street analysts forecast NOTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NOTV is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Analyst Rating

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.370

Low

5.00

Averages

5.00

High

5.00

Current: 1.370

Low

5.00

Averages

5.00

High

5.00

Lake Street

Frank Takkinen

Buy

downgrade

$6 -> $5

2025-05-08

Reason

Lake Street

Frank Takkinen

Price Target

$6 -> $5

2025-05-08

downgrade

Buy

Reason

Lake Street analyst Frank Takkinen lowered the firm's price target on Inotiv to $5 from $6 and keeps a Buy rating on the shares. Inotiv's recovery "continues to trend favorably," but the firm is taking a more conservative stance with its revenue and EBITDA estimates as it now believes its prior view of the recovery ramp was "too steep," the analyst tells investors.

Lake Street

Frank Takkinen

Hold

Strong Buy

Upgrades

$2 → $4

2024-09-30

Reason

Lake Street

Frank Takkinen

Price Target

$2 → $4

2024-09-30

Upgrades

Hold

Strong Buy

Reason

See All Ratings

About NOTV

Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.

About the author

Preview

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.